Warnke C - Search Results

1

CD34+ progenitor cells mobilized by natalizumab are not a relevant reservoir for JC virus.

Warnke C, Smolianov V, Dehmel T, Andrée M, Hengel H, Zohren F, Arendt G, Wiendl H, Haas R, Hartung HP, Adams O, Kieseier BC. Warnke C, et al. Mult Scler. 2011 Feb;17(2):151-6. doi: 10.1177/1352458510385834. Epub 2010 Nov 15. Mult Scler. 2011. PMID: 21078695

2

Physical activity is related to disease severity and fatigue, but not to relapse rate in persons with relapsing remitting multiple sclerosis - a self-reported questionnaire based study.

Schlagheck ML, Hübner ST, Joisten N, Walzik D, Rademacher A, Wolf F, Bansi J, Warnke C, Zimmer P. Schlagheck ML, et al. Among authors: warnke c. Front Neurol. 2023 Jul 31;14:1217000. doi: 10.3389/fneur.2023.1217000. eCollection 2023. Front Neurol. 2023. PMID: 37583953 Free PMC article.

3

Multidomain cognitive impairment in non-hospitalized patients with the post-COVID-19 syndrome: results from a prospective monocentric cohort.

Schild AK, Goereci Y, Scharfenberg D, Klein K, Lülling J, Meiberth D, Schweitzer F, Stürmer S, Zeyen P, Sahin D, Fink GR, Jessen F, Franke C, Onur OA, Kessler J, Warnke C, Maier F. Schild AK, et al. Among authors: warnke c. J Neurol. 2023 Mar;270(3):1215-1223. doi: 10.1007/s00415-022-11444-w. Epub 2022 Nov 23. J Neurol. 2023. PMID: 36422669 Free PMC article.

4

Disease-modifying agents for multiple sclerosis: recent advances and future prospects.

Menge T, Weber MS, Hemmer B, Kieseier BC, von Büdingen HC, Warnke C, Zamvil SS, Boster A, Khan O, Hartung HP, Stüve O. Menge T, et al. Among authors: warnke c. Drugs. 2008;68(17):2445-68. doi: 10.2165/0003495-200868170-00004. Drugs. 2008. PMID: 19016573 Review.

5

[Possibilities and risks of the monoclonal antibody alemtuzumab as a new treatment option for multiple sclerosis].

Warnke C, Kieseier BC, Zettl U, Hartung HP. Warnke C, et al. Nervenarzt. 2009 Apr;80(4):468-74. doi: 10.1007/s00115-009-2681-9. Nervenarzt. 2009. PMID: 19296065 Review. German.

6

[Progressive multifocal leukoencephalopathy. Undesirable side effect of immunotherapy].

Hartung HP, Warnke C, Hohlfeld R, Kieseier BC. Hartung HP, et al. Among authors: warnke c. Nervenarzt. 2009 Oct;80(10):1143-4, 1146-8, 1150-3. doi: 10.1007/s00115-009-2701-9. Nervenarzt. 2009. PMID: 19357826 Review. German.

7

Review of teriflunomide and its potential in the treatment of multiple sclerosis.

Warnke C, Meyer zu Hörste G, Hartung HP, Stüve O, Kieseier BC. Warnke C, et al. Neuropsychiatr Dis Treat. 2009;5:333-40. Epub 2009 Jun 10. Neuropsychiatr Dis Treat. 2009. PMID: 19557143 Free PMC article.

8

Asymptomatic reactivation of JC virus in patients treated with natalizumab.

Warnke C, Adams O, Kieseier BC. Warnke C, et al. N Engl J Med. 2009 Dec 17;361(25):2489; author reply 2489-90. N Engl J Med. 2009. PMID: 20050216 No abstract available.

9

Identification of targets and new developments in the treatment of multiple sclerosis--focus on cladribine.

Warnke C, Wiendl H, Hartung HP, Stüve O, Kieseier BC. Warnke C, et al. Drug Des Devel Ther. 2010 Jul 21;4:117-26. doi: 10.2147/dddt.s6627. Drug Des Devel Ther. 2010. PMID: 20689698 Free PMC article. Review.

10

Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided?

Warnke C, Menge T, Hartung HP, Racke MK, Cravens PD, Bennett JL, Frohman EM, Greenberg BM, Zamvil SS, Gold R, Hemmer B, Kieseier BC, Stüve O. Warnke C, et al. Arch Neurol. 2010 Aug;67(8):923-30. doi: 10.1001/archneurol.2010.161. Arch Neurol. 2010. PMID: 20697042 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

175 results

Search Page

Filters